| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 76 | 2019 | 15694 | 1.030 |
Why?
|
| Taxoids | 14 | 2013 | 967 | 0.660 |
Why?
|
| Doxorubicin | 30 | 2015 | 3005 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 46 | 2023 | 15862 | 0.610 |
Why?
|
| Paclitaxel | 19 | 2015 | 1996 | 0.560 |
Why?
|
| Antibiotics, Antineoplastic | 6 | 2002 | 726 | 0.480 |
Why?
|
| Antineoplastic Agents, Phytogenic | 12 | 2003 | 852 | 0.420 |
Why?
|
| Receptor, ErbB-2 | 9 | 2019 | 2518 | 0.320 |
Why?
|
| Fluorouracil | 20 | 2012 | 1944 | 0.290 |
Why?
|
| Neutropenia | 9 | 2023 | 968 | 0.260 |
Why?
|
| Lacrimal Duct Obstruction | 2 | 2002 | 53 | 0.240 |
Why?
|
| Neoplasm Metastasis | 21 | 2019 | 5112 | 0.240 |
Why?
|
| Sirolimus | 4 | 2015 | 814 | 0.240 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2018 | 153 | 0.230 |
Why?
|
| Cyclophosphamide | 21 | 2012 | 3001 | 0.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2011 | 840 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2018 | 479 | 0.210 |
Why?
|
| Middle Aged | 77 | 2019 | 86204 | 0.210 |
Why?
|
| Receptors, Estrogen | 12 | 2012 | 2086 | 0.210 |
Why?
|
| Adult | 70 | 2019 | 77950 | 0.200 |
Why?
|
| Aged | 62 | 2019 | 70117 | 0.180 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2023 | 882 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2019 | 5178 | 0.170 |
Why?
|
| Female | 84 | 2019 | 141928 | 0.170 |
Why?
|
| Lacrimal Apparatus | 1 | 2001 | 181 | 0.170 |
Why?
|
| Gene Expression Profiling | 7 | 2012 | 5159 | 0.170 |
Why?
|
| Drug Administration Schedule | 16 | 2011 | 3472 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 11 | 2014 | 4975 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2014 | 3890 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 4938 | 0.140 |
Why?
|
| Estrogen Receptor alpha | 2 | 2012 | 701 | 0.140 |
Why?
|
| Biomarkers, Tumor | 8 | 2014 | 10331 | 0.140 |
Why?
|
| Metaplasia | 2 | 2015 | 383 | 0.140 |
Why?
|
| Imatinib Mesylate | 2 | 2018 | 1665 | 0.140 |
Why?
|
| Humans | 89 | 2023 | 261506 | 0.130 |
Why?
|
| Disease-Free Survival | 17 | 2014 | 10001 | 0.130 |
Why?
|
| Mastectomy | 3 | 2013 | 1534 | 0.130 |
Why?
|
| Tamoxifen | 7 | 2010 | 876 | 0.130 |
Why?
|
| Drug Carriers | 4 | 2002 | 327 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 7 | 2011 | 4367 | 0.120 |
Why?
|
| Trastuzumab | 6 | 2019 | 696 | 0.120 |
Why?
|
| Estrogen Antagonists | 3 | 2001 | 184 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2014 | 8873 | 0.120 |
Why?
|
| Liposomes | 5 | 2002 | 684 | 0.110 |
Why?
|
| Bone Neoplasms | 4 | 2012 | 2576 | 0.110 |
Why?
|
| Procollagen | 1 | 2012 | 31 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 1215 | 0.110 |
Why?
|
| Mesoderm | 1 | 2015 | 404 | 0.110 |
Why?
|
| Sarcoma | 1 | 2023 | 1725 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2015 | 986 | 0.110 |
Why?
|
| Treatment Outcome | 25 | 2018 | 32848 | 0.100 |
Why?
|
| Vinblastine | 3 | 2003 | 453 | 0.100 |
Why?
|
| Breast Neoplasms, Male | 3 | 2019 | 229 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2013 | 10035 | 0.100 |
Why?
|
| Thiophenes | 2 | 2003 | 148 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2014 | 3251 | 0.100 |
Why?
|
| Genes, BRCA2 | 1 | 2013 | 309 | 0.090 |
Why?
|
| Guanidines | 3 | 1995 | 60 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2011 | 749 | 0.090 |
Why?
|
| Genes, erbB-2 | 2 | 2011 | 229 | 0.090 |
Why?
|
| Genes, BRCA1 | 1 | 2013 | 387 | 0.090 |
Why?
|
| Lacrimal Apparatus Diseases | 2 | 2002 | 137 | 0.090 |
Why?
|
| Infusions, Intravenous | 6 | 2005 | 1382 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 324 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2010 | 200 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 321 | 0.090 |
Why?
|
| Thionucleotides | 1 | 2008 | 65 | 0.080 |
Why?
|
| Combined Modality Therapy | 13 | 2012 | 8865 | 0.080 |
Why?
|
| Neoplasm Staging | 14 | 2015 | 13658 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2013 | 574 | 0.080 |
Why?
|
| Antineoplastic Agents | 10 | 2008 | 14289 | 0.080 |
Why?
|
| Uracil | 2 | 2010 | 64 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 3 | 2011 | 1290 | 0.080 |
Why?
|
| Survival Rate | 9 | 2019 | 12221 | 0.070 |
Why?
|
| Radiometry | 1 | 2013 | 980 | 0.070 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 674 | 0.070 |
Why?
|
| Aminopterin | 1 | 2006 | 30 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2012 | 1271 | 0.070 |
Why?
|
| Piperidines | 2 | 2003 | 1035 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2009 | 216 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2009 | 619 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2012 | 6150 | 0.070 |
Why?
|
| Neoplasms | 5 | 2003 | 15193 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 4892 | 0.070 |
Why?
|
| Lung Neoplasms | 8 | 2002 | 11538 | 0.070 |
Why?
|
| Prospective Studies | 11 | 2023 | 12873 | 0.060 |
Why?
|
| Deoxycytidine | 3 | 2012 | 1353 | 0.060 |
Why?
|
| Leucovorin | 2 | 2010 | 332 | 0.060 |
Why?
|
| Carcinoma | 2 | 2011 | 2578 | 0.060 |
Why?
|
| Survival Analysis | 10 | 2010 | 9180 | 0.060 |
Why?
|
| Prognosis | 10 | 2015 | 21713 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 210 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 1995 | 101 | 0.060 |
Why?
|
| Boronic Acids | 1 | 2006 | 362 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 6207 | 0.060 |
Why?
|
| Transplantation Chimera | 1 | 2003 | 155 | 0.060 |
Why?
|
| Receptors, Progesterone | 4 | 2012 | 1392 | 0.060 |
Why?
|
| Pyrazines | 1 | 2006 | 495 | 0.060 |
Why?
|
| Genomics | 2 | 2011 | 2738 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1493 | 0.050 |
Why?
|
| Quinolines | 1 | 2005 | 383 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2006 | 1090 | 0.050 |
Why?
|
| Follow-Up Studies | 9 | 2015 | 14889 | 0.050 |
Why?
|
| Algorithms | 2 | 2011 | 3890 | 0.050 |
Why?
|
| Pleural Neoplasms | 1 | 2006 | 470 | 0.050 |
Why?
|
| Estradiol | 1 | 2004 | 748 | 0.050 |
Why?
|
| Cisplatin | 6 | 2006 | 2432 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2000 | 225 | 0.040 |
Why?
|
| Tears | 1 | 2001 | 181 | 0.040 |
Why?
|
| Immunohistochemistry | 5 | 2012 | 7548 | 0.040 |
Why?
|
| Bevacizumab | 2 | 2015 | 938 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 5539 | 0.040 |
Why?
|
| Estrogens | 1 | 2003 | 751 | 0.040 |
Why?
|
| Benzamides | 2 | 2019 | 1832 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2101 | 0.040 |
Why?
|
| Everolimus | 2 | 2011 | 415 | 0.040 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 29902 | 0.040 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2000 | 145 | 0.040 |
Why?
|
| Epirubicin | 2 | 2012 | 157 | 0.040 |
Why?
|
| Forecasting | 2 | 2011 | 694 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2006 | 1616 | 0.040 |
Why?
|
| Vidarabine | 1 | 2003 | 1341 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 2508 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 4988 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2013 | 4557 | 0.040 |
Why?
|
| Time Factors | 6 | 2010 | 12926 | 0.040 |
Why?
|
| Fibrosis | 1 | 2001 | 793 | 0.040 |
Why?
|
| Capecitabine | 2 | 2012 | 388 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 2231 | 0.040 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1999 | 222 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 2316 | 0.030 |
Why?
|
| Remission Induction | 4 | 2005 | 3569 | 0.030 |
Why?
|
| Nausea | 4 | 2006 | 525 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1313 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3518 | 0.030 |
Why?
|
| Drug Resistance | 2 | 1994 | 587 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2006 | 6550 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 4298 | 0.030 |
Why?
|
| Agranulocytosis | 3 | 2006 | 79 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2013 | 2803 | 0.030 |
Why?
|
| Cytokines | 1 | 2004 | 2809 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2003 | 2238 | 0.030 |
Why?
|
| Adenocarcinoma | 6 | 2001 | 7789 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 2011 | 1363 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1995 | 250 | 0.030 |
Why?
|
| Patient Selection | 3 | 2010 | 2055 | 0.030 |
Why?
|
| Male | 17 | 2019 | 123000 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1994 | 57 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2005 | 2232 | 0.030 |
Why?
|
| Methotrexate | 2 | 2010 | 999 | 0.030 |
Why?
|
| Fever | 3 | 2002 | 497 | 0.030 |
Why?
|
| Deficiency Diseases | 1 | 1973 | 11 | 0.030 |
Why?
|
| Etoposide | 3 | 2006 | 870 | 0.030 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1973 | 25 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 521 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 1994 | 259 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2012 | 87 | 0.030 |
Why?
|
| Disease Progression | 4 | 2006 | 6682 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2004 | 1544 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 1994 | 253 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2003 | 1299 | 0.030 |
Why?
|
| Pyridines | 1 | 2019 | 1244 | 0.030 |
Why?
|
| Mutation | 1 | 2012 | 15179 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 823 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2012 | 204 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 85 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 615 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2010 | 10 | 0.020 |
Why?
|
| Genes | 1 | 2012 | 491 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 2326 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2011 | 183 | 0.020 |
Why?
|
| Tegafur | 1 | 2010 | 50 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2008 | 1216 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1742 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 202 | 0.020 |
Why?
|
| Organophosphorus Compounds | 1 | 2009 | 101 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 1546 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2011 | 331 | 0.020 |
Why?
|
| Young Adult | 3 | 2015 | 21445 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 452 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 3203 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2006 | 1914 | 0.020 |
Why?
|
| Lymphatic Metastasis | 3 | 2005 | 4844 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2008 | 2307 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 1678 | 0.020 |
Why?
|
| Endometrium | 2 | 2003 | 470 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 700 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2010 | 305 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 1084 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 1323 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1994 | 1375 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 745 | 0.020 |
Why?
|
| Liver | 2 | 2013 | 2961 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 4971 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2012 | 11965 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 756 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2004 | 2292 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2010 | 6869 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 1479 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 1972 | 0.020 |
Why?
|
| Leukopenia | 1 | 2006 | 151 | 0.020 |
Why?
|
| Adolescent | 4 | 2011 | 31252 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 2283 | 0.020 |
Why?
|
| Adenoviruses, Human | 1 | 2006 | 181 | 0.020 |
Why?
|
| Alopecia | 1 | 2006 | 126 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2006 | 227 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2005 | 121 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2006 | 392 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 1994 | 3719 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 2927 | 0.020 |
Why?
|
| Anthraquinones | 1 | 1984 | 27 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2005 | 226 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 1985 | 69 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 1546 | 0.020 |
Why?
|
| Transgenes | 1 | 2006 | 557 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 310 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2014 | 37905 | 0.020 |
Why?
|
| Half-Life | 1 | 2004 | 259 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2008 | 649 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 2 | 1 | 2003 | 4 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2003 | 8 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 1360 | 0.010 |
Why?
|
| Bortezomib | 1 | 2006 | 543 | 0.010 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2003 | 44 | 0.010 |
Why?
|
| Sulindac | 1 | 2003 | 51 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2594 | 0.010 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2003 | 103 | 0.010 |
Why?
|
| Antibody Formation | 2 | 1995 | 383 | 0.010 |
Why?
|
| Gene Expression | 1 | 2012 | 3570 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 156 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 716 | 0.010 |
Why?
|
| Graft vs Tumor Effect | 1 | 2003 | 139 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 408 | 0.010 |
Why?
|
| ROC Curve | 1 | 2006 | 1183 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2011 | 2054 | 0.010 |
Why?
|
| Postmenopause | 1 | 2004 | 378 | 0.010 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2003 | 112 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 461 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 253 | 0.010 |
Why?
|
| Risk Factors | 2 | 2010 | 17523 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 3639 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2005 | 731 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 3154 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 641 | 0.010 |
Why?
|
| Prodrugs | 1 | 2003 | 217 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 869 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2330 | 0.010 |
Why?
|
| Recurrence | 1 | 2010 | 4758 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 519 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 482 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 159 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2006 | 992 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 478 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 2005 | 611 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 1694 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1544 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1994 | 7222 | 0.010 |
Why?
|
| Anemia | 1 | 2006 | 689 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2003 | 1053 | 0.010 |
Why?
|
| Melphalan | 1 | 2003 | 834 | 0.010 |
Why?
|
| Heart | 2 | 2001 | 1223 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 4549 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 2001 | 187 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2003 | 690 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 588 | 0.010 |
Why?
|
| Frail Elderly | 1 | 2000 | 118 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 1038 | 0.010 |
Why?
|
| Apgar Score | 1 | 1999 | 55 | 0.010 |
Why?
|
| Disease | 1 | 2000 | 165 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1538 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 1013 | 0.010 |
Why?
|
| Prednisone | 1 | 2001 | 984 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1985 | 1824 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 1239 | 0.010 |
Why?
|
| Antiemetics | 1 | 1998 | 125 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3981 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 2588 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 1989 | 5437 | 0.010 |
Why?
|
| Birth Weight | 1 | 1999 | 374 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 2843 | 0.010 |
Why?
|
| Edema | 1 | 1998 | 267 | 0.010 |
Why?
|
| Vincristine | 1 | 2001 | 1511 | 0.010 |
Why?
|
| Anxiety | 1 | 2004 | 1179 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1999 | 577 | 0.010 |
Why?
|
| Radiography | 1 | 2001 | 1904 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 6009 | 0.010 |
Why?
|
| Complement C4 | 1 | 1995 | 15 | 0.010 |
Why?
|
| Isoantigens | 1 | 1995 | 62 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 2450 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 703 | 0.010 |
Why?
|
| Pain | 1 | 2004 | 1658 | 0.010 |
Why?
|
| Gestational Age | 1 | 1999 | 1069 | 0.010 |
Why?
|
| Fetus | 1 | 1999 | 601 | 0.010 |
Why?
|
| Complement C3 | 1 | 1995 | 78 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1995 | 334 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1999 | 603 | 0.010 |
Why?
|
| Complement Activation | 1 | 1995 | 94 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 1879 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2000 | 1026 | 0.010 |
Why?
|
| Texas | 1 | 2005 | 6311 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1994 | 49 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 58 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1984 | 425 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1998 | 500 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1995 | 553 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1998 | 1450 | 0.010 |
Why?
|
| Magnesium | 1 | 1994 | 160 | 0.010 |
Why?
|
| Neuromuscular Diseases | 1 | 1994 | 63 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1973 | 16 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 1973 | 53 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 1973 | 78 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1999 | 732 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 4757 | 0.010 |
Why?
|
| Species Specificity | 1 | 1994 | 777 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2003 | 2638 | 0.010 |
Why?
|
| Animals | 2 | 1994 | 59536 | 0.010 |
Why?
|
| Hypotension | 1 | 1994 | 210 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 5319 | 0.010 |
Why?
|
| Canada | 1 | 1973 | 429 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1973 | 339 | 0.010 |
Why?
|
| United States | 1 | 2008 | 15433 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 2000 | 1341 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2003 | 9244 | 0.010 |
Why?
|
| Age Factors | 1 | 2000 | 5377 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 2967 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 4532 | 0.010 |
Why?
|
| Pedigree | 1 | 1973 | 1890 | 0.010 |
Why?
|
| Thrombocytopenia | 2 | 1984 | 846 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1999 | 4320 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 1555 | 0.010 |
Why?
|
| Phosphoramide Mustards | 1 | 1988 | 37 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1995 | 2358 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1984 | 4849 | 0.000 |
Why?
|
| Pregnancy | 1 | 1999 | 7573 | 0.000 |
Why?
|
| Peptichemio | 1 | 1985 | 12 | 0.000 |
Why?
|
| Esophageal Fistula | 1 | 1985 | 27 | 0.000 |
Why?
|
| Esophageal Stenosis | 1 | 1985 | 83 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1973 | 2086 | 0.000 |
Why?
|
| Mitoxantrone | 1 | 1984 | 216 | 0.000 |
Why?
|
| Esophagitis | 1 | 1985 | 202 | 0.000 |
Why?
|
| Myocardium | 1 | 1989 | 1313 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1995 | 3341 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1984 | 408 | 0.000 |
Why?
|
| Mice | 1 | 1994 | 34495 | 0.000 |
Why?
|